A new clinical trial demonstrates a novel, personalized neoantigen vaccine therapy showed promising anti-tumor efficacy in patients with liver cancer who failed their original front-line treatment. The therapy induced potent induction of T cell immunity and regressed tumors in preclinical model studies.
Researchers have developed a DNA vaccine against zika virus that induces a strong immune response and protects mice from the virus. The vaccine uses genetic engineering to encode specific viral proteins and stimulates an adaptive immune response, with high levels of neutralizing antibodies produced.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
Researchers at HKUMed developed a PD-1-enhanced DNA vaccine that induces sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years without cART, demonstrating the potential of this strategy as a third-generation DNA vaccine for AIDS prevention and immunotherapy.
A new respiratory vaccine has been shown to provide complete protection against lethal SARS-CoV-2 challenge in mice. The vaccine uses a DNA encoding a viral protein and is delivered through the mucous membranes, targeting immune cells in the nose and lungs.
Researchers have developed a new approach to stopping viral infections using a live-attenuated DNA virus vaccine. The method employs centanamycin to generate an altered virus that can't reproduce inside cells, stimulating the host's immune system to recognize and eliminate the invading virus particles.
Researchers developed a DNA vaccine containing multiple parts of the virus, including ones that don't mutate as frequently. The vaccine protected mice against serious infection from the beta variant and activated immune cells recognizing the coronavirus found in bats.
Researchers at The Wistar Institute have developed a DNA-encoded immunogen that produces tier-2 neutralizing antibodies in mice, opening up new possibilities for HIV vaccine development. The study demonstrates the potential of using native-like trimer to generate broadly neutralizing antibody responses.
A new study reveals the sophisticated mechanism by which adenoviruses infect human cells and transfer foreign DNA into their nucleus. Protein V plays a crucial role in increasing the virus particle's stability and preventing premature DNA release, which triggers an anti-viral alarm system.
Researchers have developed a microneedle patch that delivers a COVID-19 DNA vaccine into the skin, causing strong immune responses in cells and mice. The patch can be stored at room temperature for over 30 days, making it an important tool for global COVID-19 vaccine distribution.
Researchers developed a DNA vaccine encoding SARS-CoV-2 spike protein, which induced long-lasting antibodies in mice and hamsters. The vaccine showed protective efficacy against COVID-19 infection in hamsters, with no loss of body weight or viral RNA in their lungs.
Scientists at The Wistar Institute have developed a synthetic DNA vaccine against Powassan virus, which causes a deadly tick-borne disease with neurological consequences. The vaccine elicits broad immune responses in mice and provides protection in a challenge animal model.
Researchers detected oral HPV DNA in 6.2% of teen and young adult female participants, with detection decreasing over time since becoming sexually active. The study suggests that the HPV vaccine is less effective against certain types of oral HPV in vaccinated individuals compared to those who are fully unvaccinated.
Researchers developed a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) that completely protects against lethal infection in ferrets. The vaccine induces both neutralizing antibody response and multifunctional T cell immunity.
Researchers have developed a novel DNA vaccine capable of inducing protective immunity against the Mayaro virus, which causes fever, rash, and joint pain. The vaccine demonstrated complete protection from death and clinical signs of infection in a mouse model, offering a promising solution for combating this emerging infectious disease.
A novel synthetic DNA vaccine targeting the Mayaro virus envelope protein provides complete protection from disease in preclinical studies. The vaccine induces potent protective and virus-specific immune responses, including neutralizing antibodies and cellular responses.
Researchers developed a novel DNA vaccine that protected mice against multiple H3N2 viruses and severe illness, offering a promising approach to elicit an immune response against diverse strains. The vaccine strategy represents a step forward in eliminating the need for seasonal reformulation of influenza vaccines.
A novel synthetic DNA vaccine offers complete protection from Zaire Ebolavirus infection, with strong immune responses detected one year after the last dose. The vaccine's efficacy and durability support its potential as a new tool for protection against Ebola virus.
Researchers at UTMB create DNA-based vaccine that cuts production costs and storage needs by up to 80%. The new platform has potential to serve as a universal platform for developing live-attenuated vaccines for many viral pathogens.
A collaborative development of a dengue vaccine candidate has been announced by Institut Pasteur, BioNet-Asia and In-Cell-Art. The project aims to develop a single injection containing diverse antigens that vary in key positions to induce immune responses with unprecedented breadth and potency.
Researchers are testing a two-pronged approach combining a DNA vaccine and antibody to boost the immune response against tumors in patients with advanced stage CRC. Preliminary mouse studies showed promising results, including an immune memory that prevented re-challenge with the same tumor.
A new DNA-based Zika vaccine candidate has demonstrated both safety and the ability to elicit an immune response against Zika in humans. The phase 1 clinical trial showed that participants produced an immune response against Zika with minimal adverse effects.
A recent study published in Frontiers in Cellular and Infection Microbiology has made significant progress in developing a DNA vaccine against the dengue virus. Researchers have successfully induced persistent humoral and cellular immune responses in mice, providing efficient protection against lethal challenge from one of the four ser...
A novel DNA vaccine approach targets Wilm's tumor gene 1 (WT1), breaking immune tolerance and inducing robust T cell responses. The vaccine shows promise in generating improved immunity to WT1-expressing cancers, with therapeutic effects observed in mice.
Scientists develop a nanoparticle-based method for delivering therapeutic molecules into cells, enabling the induction of strong immune responses against various viruses and diseases. The technique, which harnesses electrically activated gold nanoparticles, demonstrates safety and efficacy in animal studies.
Researchers at Kansas State University developed a promising Zika virus vaccine using DNA technology. The vaccine is safer and more effective against the virus, offering long-term protection at a lower cost.
A new preclinical study suggests that an effective Zika vaccine is achievable. Two vaccine candidates were tested and found to be safe and protective against the virus in mice. The purified inactivated virus (PIV) vaccine is being developed and planned for human testing later this year.
Two experimental Zika vaccines fully protected mice from infection, even after four weeks without inoculation. The DNA and inactivated virus vaccines induced virus-specific antibodies, correlating with protection against infection.
A new DNA vaccine targeting p62 has shown promising results in alleviating chronic inflammation and osteoporosis by exploiting the protein's role in autophagy. The vaccine, currently in phase I clinical trials, may offer a safe treatment for inflammatory bone loss.
A new hybrid vehicle has been developed to deliver DNA vaccines that can fight HIV, cancer, influenza, and other diseases. The technology improves the delivery of genes to the immune system, increasing its effectiveness in treating major illnesses.
A new adjuvant, IL-33, enhances the immune response to cancer cells and viruses. The protein is being studied as a potential boost for vaccines against pathogens.
A new DNA vaccine, p(Aβ3–10)10-C3d-p28, was developed to induce a Th2 immune response against amyloid-beta in Alzheimer's disease mice. The vaccine successfully elicited high titers of anti-amyloid-β antibodies and shifted the cellular immune response towards a Th2 phenotype.
Researchers at Arizona State University are developing a new DNA nanostructure-based vaccine to combat nicotine dependence. The approach uses precision control over the placement of antigenic components to stimulate an immune response and recruit antibodies capable of binding with nicotine, potentially improving efficacy and safety.
Researchers at MIT have developed a new type of vaccine-delivery film that gradually releases DNA coding for viral proteins, potentially overcoming safety risks and improving effectiveness. The film is implanted under the skin using microneedles and degrades over time, releasing the vaccine over days or weeks.
A clinical trial has shown robust vaccine-specific antibody responses and strong T cell immune responses in patients vaccinated with a WT1 DNA vaccine. The vaccine is also safe and well-tolerated, paving the way for further trials in acute myeloid leukaemia (AML) patients.
Researchers at Arizona State University develop first vaccine complex that can be delivered safely and effectively by piggybacking onto self-assembled, three-dimensional DNA nanostructures. The vaccine complexes trigger a robust immune response up to 9-fold higher than traditional methods.
Researchers have successfully protected laboratory animals from lethal hantavirus disease using a DNA vaccine and duck eggs. The study demonstrates the feasibility of this novel approach, which could supplement or replace existing treatments for HPS.
Researchers demonstrate that an anti-caries DNA vaccine, pGJA-P/VAX, combined with a Salmonella protein adjuvant, enhances saliva IgA responses and protects against dental caries. The study shows that the adjuvant promotes specific immunoglobulin A responses in saliva and offers better protection against caries.
Researchers found that a DNA vaccine expressing a key H5N1 protein enhanced the immune response to an H5N1 avian influenza vaccine. The prime-boost regimen produced high levels of protective antibodies and broadly neutralizing antibodies against the HA stem, a region relatively constant across many strains of influenza viruses.
Scientists have made significant progress in developing effective delivery systems and efficient biomanufacturing strategies for DNA vaccines. Novel methodologies have emerged, including transdermal patches, electroporation, and plasmid purification techniques.
Researchers have developed a faster-growing E. coli strain suitable for mass production of high-quality DNA for vaccines and gene therapy. The modified strain retains useful traits while growing as quickly as other industrial strains.
A Phase I study has begun to evaluate a combination DNA prime/MVA vector boost vaccine regimen to protect against diverse subtypes of HIV-1. The study will enroll 92 participants and test two intramuscular delivery methods for the DNA prime, Biojector 2000 and CELLECTRA EP, to compare their effects on immune response.
Advances in DNA vaccine technology have led to improved efficacy and effectiveness compared to traditional vaccines. New approaches in electroporation and vector design are driving growth in the field, with several promising therapeutic vaccines being developed.
The InVacc platform generates vaccines with enhanced properties, triggering a broader immune response and enabling faster protection against deadly diseases. The platform overcomes limitations of traditional DNA vaccines by decoding genetic material and presenting antigens to the immune system.
Researchers at the University of Pennsylvania School of Medicine have developed a potential new way to vaccinate against avian flu by using synthetic DNA vaccines that induce broad immune responses against pandemic flu. This approach could allow for quick mobilization during an epidemic and has implications for non-avian types of flu.
New DNA vaccine technology targets DCs for enhanced immune response; studies in mice show improved protection against viruses and potential applications for cystic fibrosis modeling. Genetic manipulation creates large animal models of CF, providing new avenues for disease research.
New DNA vaccine data identified in mice shows increased immune response by targeting HIV protein gp41 to DCs with a single-chain Fv antibody. This approach induced stronger T cell responses and protected mice from the virus more efficiently than current DNA vaccines.
Researchers have found that tattooing is a more effective way of delivering DNA vaccines than intramuscular injection, producing stronger humoral and cellular immune responses. This method could have a role in routine vaccination of cattle or delivering therapeutic vaccines to humans.
Researchers at the University of Pennsylvania School of Medicine have discovered that an immune system gene can enhance a vaccine used to study HIV in macaque monkeys, providing greater protection against simian HIV. The study found that the addition of Interleukin-15 boosts the effects of a vaccine derived from the DNA of simian HIV.
A Vaxfectin-formulated measles DNA vaccine has elicited protective levels of neutralizing antibodies and sterilizing immunity in juvenile and infant nonhuman primates, offering proof of concept for the technology. The vaccine showed no vaccine-related adverse events and was well-tolerated.
A human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began in December 2006. The vaccine instructs human cells to make proteins that act as a vaccine against the virus, providing broad immune responses without infectious material.
Two candidate vaccines have shown promise in a recent study, demonstrating an immune response in healthy adults and inducing positive CD4 T cell responses. The combination of DNA priming and rAd5 boosting may lead to higher levels of T cell responses and improved vaccine efficacy.
A Phase 1 trial of an Ebola DNA vaccine demonstrated strong immune responses in all fully vaccinated volunteers. The vaccine, developed by Vical, was well-tolerated and showed effectiveness against Ebola-specific antibodies.
A DNA vaccine could be a powerful tool to combat the 'bird flu' pandemic, potentially produced in as little as two or three weeks. The technique is largely untested in humans, but it might help slow the spread of the disease if enough conventional vaccines aren't available.
The experimental DNA vaccine is composed of a small piece of DNA that contains genes coding for two key surface proteins of the West Nile virus. In the study, 15 healthy volunteers will receive three injections of the vaccine into the upper arm to monitor their immune response.
Researchers developed a DNA vaccine that protected nonhuman primates from both smallpox and monkeypox, offering a safer alternative to existing live virus vaccines. The vaccine used four genes from vaccinia virus and was shown to elicit a robust immune response in primates.
The NIAID-developed DNA vaccine significantly reduced SARS virus levels in infected mice, with antibodies alone responsible for the dramatic reduction. This breakthrough demonstrates the effectiveness of a novel vaccine approach against SARS, paving the way for future human clinical trials.
A DNA vaccine has been shown to protect against anthrax, with the protective antigen (PA)-based vaccine proving more effective than the lethal factor (LF)-based vaccine. The study found that immunization with PA induces antibodies capable of neutralizing toxin and conferring protection.
Researchers at Stanford Medicine developed a targeted DNA vaccine that can predict and treat autoimmune diseases like M.S. by analyzing antibody profiles. The vaccine uses tolerization to knock out harmful immune responses while leaving the rest of the system functional, offering new hope for personalized therapies.
The University of Maryland Biotechnology Institute has licensed its DNA Bactofection technology to Microscience, enabling the delivery of DNA vaccines for viral diseases and cancers. Microscience will use the technology to develop a range of DNA vaccines, including those for typhoid, travellers' diarrhea, and hepatitis B virus infection.